BlackRock Unit Reports 5.9% Passive Stake In Vanda Pharmaceuticals
BlackRock Portfolio Management holds 3,587,013 Vanda shares, and says it has no aim to influence control of the drugmaker.
BlackRock Portfolio Management LLC, an asset-management unit of BlackRock, reports owning 3,587,013 shares of Vanda Pharmaceuticals, or 5.9% of the common stock, in a passive ownership disclosure filed Tuesday with the SEC. Vanda, a drugmaker, announced positive late-stage trial results for a GLP-1 nausea drug the same day.
Inside the 5.9% position
The filing, a Schedule 13G, gives BlackRock Portfolio Management sole voting power over 3,228,683 shares and no shared voting power. It classifies the filer as a parent holding company, and lists September 30, 2026 as the date of the event that triggered the report.
BlackRock certified that the shares are held in the ordinary course of business, not to change or influence control of Vanda. The filing says various persons have the right to receive dividends or sale proceeds, and that no one person's interest exceeds 5% of the shares outstanding.
A filed exhibit lists the BlackRock business units covered, among them BlackRock Advisors, Aperio Group, BlackRock Fund Advisors and BlackRock Institutional Trust Company.
A GLP-1 nausea trial lands the same day
Vanda develops and sells prescription drugs. Its commercial products are Fanapt, HETLIOZ, PONVORY and NEREUS, which was approved in December 2025 for preventing motion-induced vomiting.
On Tuesday the company announced positive results from a late-stage trial of Nereus (tradipitant), an oral drug meant to prevent vomiting tied to GLP-1 weight-loss and diabetes injections. Vomiting occurred in 43.0% of treated patients versus 58.5% on placebo.
Vanda shares closed at $3.99 on Tuesday, for a market value of $238 million.
Vanda plans to discuss the results with the FDA before submitting a supplemental New Drug Application for preventing GLP-1-related vomiting.
Sources
- SCHEDULE 13G — BlackRock Portfolio Management LLC re: Vanda Pharmaceuticals Inc. (VNDA) — SEC EDGAR
- SCHEDULE 13G Exhibit 99 — EXHIBIT 99: ITEM 7 — SEC EDGAR
- Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes - Vanda Pharmaceu — benzinga.com
- Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting – Company Announcement - FT.com — Financial Times
